Dr Kirsty McDowell
- Clinical Research Fellow (Cardiovascular & Metabolic Health)
- Honorary Clinical Fellow (School of Cardiovascular & Metabolic Health)
The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
Butt, J. H. et al. (2024) Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan. ESC Heart Failure, 11(1), pp. 65-77. (doi: 10.1002/ehf2.14558) (PMID:37813587) (PMCID:PMC10804200)
McDowell, K., Adamson, C., Jackson, C., Campbell, R., Welsh, P. , Petrie, M. C. , McMurray, J. J.V. , Jhund, P. and Herring, N. (2023) Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes. European Journal of Heart Failure, (doi: 10.1002/ejhf.3085) (PMID:37937329) (Early Online Publication)
Glen, C., Adam, S., McDowell, K., Waterston, A., Tan, Y. Y., Petrie, M. C. , Coats, C. J. and Lang, N. N. (2023) Cardiotoxicity of BRAF/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores. JACC: CardioOncology, 5(5), pp. 628-637. (doi: 10.1016/j.jaccao.2023.04.004) (PMID:37969652) (PMCID:PMC10635885)
McDowell, K. et al. (2023) Incremental prognostic value of biomarkers in PARADIGM-HF. European Journal of Heart Failure, 28(8), 1406-1414-1406-1414. (doi: 10.1002/ejhf.2887) (PMID:37191207)
Docherty, K. F. et al. (2023) Association of carbohydrate antigen 125 on the response to dapagliflozin in patients with heart failure. Journal of the American College of Cardiology, 82(2), pp. 142-157. (doi: 10.1016/j.jacc.2023.05.011) (PMID:37407113)
McDowell, K., Jhund, P. S. and McMurray, J. J.V. (2022) Reply to 'sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials'. European Journal of Heart Failure, 24(10), p. 1994. (doi: 10.1002/ejhf.2686) (PMID:36093864)
McDowell, K. and Docherty, K. F. (2022) Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure? European Heart Journal: Quality of Care and Clinical Outcomes, 8(4), pp. 371-373. (doi: 10.1093/ehjqcco/qcab088) (PMID:34921601) (PMCID:PMC9170565)
McDowell, K. et al. (2022) Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. European Journal of Heart Failure, 24(6), pp. 1066-1076. (doi: 10.1002/ejhf.2433) (PMID:35064721)
Butt, J. H. et al. (2024) Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan. ESC Heart Failure, 11(1), pp. 65-77. (doi: 10.1002/ehf2.14558) (PMID:37813587) (PMCID:PMC10804200)
McDowell, K., Adamson, C., Jackson, C., Campbell, R., Welsh, P. , Petrie, M. C. , McMurray, J. J.V. , Jhund, P. and Herring, N. (2023) Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes. European Journal of Heart Failure, (doi: 10.1002/ejhf.3085) (PMID:37937329) (Early Online Publication)
Glen, C., Adam, S., McDowell, K., Waterston, A., Tan, Y. Y., Petrie, M. C. , Coats, C. J. and Lang, N. N. (2023) Cardiotoxicity of BRAF/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores. JACC: CardioOncology, 5(5), pp. 628-637. (doi: 10.1016/j.jaccao.2023.04.004) (PMID:37969652) (PMCID:PMC10635885)
McDowell, K. et al. (2023) Incremental prognostic value of biomarkers in PARADIGM-HF. European Journal of Heart Failure, 28(8), 1406-1414-1406-1414. (doi: 10.1002/ejhf.2887) (PMID:37191207)
Docherty, K. F. et al. (2023) Association of carbohydrate antigen 125 on the response to dapagliflozin in patients with heart failure. Journal of the American College of Cardiology, 82(2), pp. 142-157. (doi: 10.1016/j.jacc.2023.05.011) (PMID:37407113)
McDowell, K., Jhund, P. S. and McMurray, J. J.V. (2022) Reply to 'sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials'. European Journal of Heart Failure, 24(10), p. 1994. (doi: 10.1002/ejhf.2686) (PMID:36093864)
McDowell, K. and Docherty, K. F. (2022) Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure? European Heart Journal: Quality of Care and Clinical Outcomes, 8(4), pp. 371-373. (doi: 10.1093/ehjqcco/qcab088) (PMID:34921601) (PMCID:PMC9170565)
McDowell, K. et al. (2022) Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. European Journal of Heart Failure, 24(6), pp. 1066-1076. (doi: 10.1002/ejhf.2433) (PMID:35064721)